This inventor holds 37 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Alkermes Pharma Ireland Limited, Stealth Biotherapeutics Inc., Centrexion Therapeutics Corporation. Active years: 2014-2025.
Location History:
- Newton, MA (US) (2020)
- Bedford, MA (US) (2014 - 2024)
Company Filing History:
16 out of 164 
16 out of 69 
3 out of 36 
Years Active: 2014-2025
Areas of Expertise:
Title: Scott M Duncan: A Leader in Pharmaceutical Innovations
Introduction: Scott M Duncan, based in Bedford, Massachusetts, is a renowned inventor with an impressive portfolio of 35 patents. His contributions have significantly advanced the field of pharmaceuticals, particularly in drug formulation and delivery systems.
Latest Patents: Among his latest innovations, Duncan has developed various crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH. This patent discloses multiple crystalline salt forms, enhancing the stability and efficacy of this compound. Additionally, he has worked on prodrugs of fumarates and their applications in treating various diseases, providing novel compounds and pharmaceutical compositions critical for therapeutic advancements.
Career Highlights: Throughout his career, Scott M Duncan has collaborated with leading companies in the pharmaceutical industry, including Alkermes Pharma Ireland Limited and Stealth Biotherapeutics Inc. His work at these organizations has been pivotal in driving forward innovative solutions to complex medical challenges.
Collaborations: Duncan has had the privilege of working with talented colleagues, including Tarek A Zeidan and Christopher P Hencken. These collaborations reflect a shared commitment to pushing the boundaries of pharmaceutical research and development.
Conclusion: Scott M Duncan's extensive experience and innovative mindset have positioned him as a key figure in the realm of pharmaceuticals. With numerous patents to his name, his ongoing contributions are sure to have a lasting impact on the industry and the patients who benefit from his work.